Gabapentin Capsule
Product Images NDC 60760-940

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-940). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (02ae9973 70b1 4bcb A7aa E48351906e74 01)

A text panel showing the formula to calculate creatinine clearance (CLCr), accounting for age, weight, sex, and serum creatinine levels. It details the equation used to estimate kidney function, specifying an adjustment factor for female patients.*

FDA Label Image

Figure1 (02ae9973 70b1 4bcb A7aa E48351906e74 02)

Chemical structure diagram of gabapentin showing a cyclohexane ring attached to an amino methyl group and a carboxymethyl group, representing the active ingredient gabapentin.*

FDA Label Image

Image 1 (02ae9973 70b1 4bcb A7aa E48351906e74 03)

A line graph comparing mean pain scores over an 8-week period between placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline through week 8, including a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10, with Gabapentin showing a greater decrease in pain scores compared to placebo.*

FDA Label Image

Image 2 (02ae9973 70b1 4bcb A7aa E48351906e74 04)

Line graph depicting mean pain scores over seven weeks comparing placebo and two doses of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis shows weeks, including a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Gabapentin groups show a decrease in pain scores compared to placebo.*

FDA Label Image

Image 3 (02ae9973 70b1 4bcb A7aa E48351906e74 05)

A bar chart titled 'Proportion of Responders' showing the percentage of patients with at least 50% reduction in pain score at the endpoint of controlled PHN studies. It compares placebo (PBO) with Gabapentin (GBP) doses 1800 mg and 2400 mg in Study 2, and placebo versus GBP 3600 mg in Study 1.*

FDA Label Image

Image 4 (02ae9973 70b1 4bcb A7aa E48351906e74 06)

A scatter plot showing the difference percentage versus daily dose (mg) for Gabapentin across three studies labeled as study a, study b, and study c. The x-axis represents daily dose in mg ranging from 600 to 1800, and the y-axis represents percentage difference, with data points marked for each study at various dose levels.*

FDA Label Image

Label (Gabapentin 300mg 60ct 60760 940 60)

Label for Gabapentin Capsules USP, 300 mg, containing 60 capsules. The label indicates the active ingredient as Gabapentin USP 300 mg per capsule. It includes storage instructions, dosage direction referencing the package insert, and pharmacist dispensing information. The product is packaged by St. Mary's Medical Park Pharmacy in Oro Valley, AZ, and manufactured by Strides Pharma Science Limited in India. The NDC is listed as 60760-940.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.